Childhood esotropia (ET) is a common cause of visual disability, and its early management is critical for optimal visual and developmental outcomes.
The proposed study addresses a need to evaluate botulinum toxin A (BTX-A) as a less invasive, cost-effective alternative to incisional strabismus surgery. If BTX-A is demonstrated to be non-inferior to incisional strabismus surgery in treating ET >10 to ≤30PD, this could reduce surgical and anesthesia-related risks in infants, lower the economic burden on families and healthcare systems, and reduce disparities in access to care, particularly in underserved settings where surgical resources are limited.

Start Date01 Jan 2027

Sponsor / Collaborator

Jaeb Center For Health Research Foundation, Inc.

[+1]

NCT07295288

/ Not yet recruitingPhase 4IIT

Investigating the Efficacy of Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis Management

Facial synkinesis is a condition that occurs following facial nerve (CN7) injury, typically secondary to Bell's palsy, trauma, surgery (e.g., acoustic neuroma resection), or malignancy. Synkinesis is due to aberrant regeneration of the facial nerve, where axons regrow improperly and result in misdirected innervation of facial muscles. This results in involuntary, uncoordinated muscle movements, where activation of one muscle group triggers unintended contractions in others. Standard treatment of facial synkinesis involves botulinum toxin (BT) injections into muscles controlled by CN7 to reduce these unwanted movements. However, patients often anecdotally report that adding BT injections into non-CN7 innervated muscle groups, such as the masseter and temporalis muscles, improve their synkinesis symptoms. This study therefore aims to assess whether adding BT injections to non-CN7 innervated muscle groups, specifically the masseter and temporalis muscle, can improve treatment outcomes for people with facial synkinesis. This study will use a crossover design, where each participant will serve as their own control to compare treatment effects. In the first treatment arm, patients will receive only their standard BT injections into muscle groups controlled by CN7 - no other muscles will be treated. In the second treatment arm, will receive the same standard BT injections in CN7 muscles, plus additional injections into masseter and temporalis muscles. Patients will be randomized to a specific treatment arm at their first visit. At their second visit, they will be randomized to the other treatment arm, in standard crossover study design. Pre- and post-treatment surveys will be collected to assess the benefit of adding non-CN7 muscle groups.

Start Date01 Jul 2026

Sponsor / Collaborator

Vanderbilt University Medical Center

NCT05393921

/ WithdrawnPhase 4IIT

The Clinical Efficacy of Intravesical Botox Injections When Combined With HoLEP Surgery in Patients With Benign Prostatic Hyperplasia and Overactive Bladder

Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in men. Almost 90% of men in their 70s report lower urinary tract symptoms related to BPH. These symptoms carry a significant negative impact on the patients' quality of life.
Despite the wide availability of surgical offerings to relieve bladder outlet obstruction such as transurethral resection of the prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP), and prostatectomy, many patients still suffer from persistent LUTS after undergoing these. A study describing postoperative outcomes following HoLEP revealed that patients with severe lower urinary tract symptoms, storage-positive sub-score, and high maximum urinary flow rate before the surgery were affected by a rebound of mainly storage symptoms 6-8 weeks after HoLEP and prolonged recovery from LUTS with 7.4% of them presenting for persistent urge complaints.
Optimizing the management approach for these patients has been limited by lack of high level evidence-based recommendations and expert consensus. Intravesical botox injections are well-established therapeutic options for several urinary disorders. The current practice offers intravesical botox injections to patients who suffer from persistent urinary symptoms few months after their BPH procedure. This study aims to evaluate if giving botox injections at the time of the HoLEP surgery would yield a better outcome than performing the two procedures separately at different times (few months apart).
The concomitant use of botox injection during bladder de-obstructing procedures has been previously studied in TURP and have showed a significant reduction of incontinence episodes and OAB symptoms in the group that were treated with botox injections after 36 weeks post TURP. This data may suggest promising potential of this intervention in managing persistent OAB symptoms in patients with BOO. However, the efficacy of combining HoLEP and bladder Botox injections has not been systematically studied and evaluated.
The aim of this study is to evaluate the effect of intravesical Botox injections on lower urinary tract symptoms (LUTS) when administered during HoLEP surgery in patients with bladder outlet obstruction (BOO) and overactive bladder symptoms (OAB). The investigators are interested in comparing the postoperative outcome in terms of recovery and symptom relief in patients who performed HoLEP surgery with bladder Botox injections versus those who performed HoLEP surgery only at 2 weeks,1 month, 3 months, and 6 months postoperatively.
The investigators hypothesize that administering bladder botox injections during HoLEP surgery is a combination treatment that will result in faster and more potent symptom relief compared to patients who received only a HoLEP surgery for their obstructive and irritative symptoms.

Start Date01 Jun 2026

Sponsor / Collaborator

University Hospitals Cleveland Medical Center

100 Clinical Results associated with Onabotulinumtoxin A

100 Translational Medicine associated with Onabotulinumtoxin A

100 Patents (Medical) associated with Onabotulinumtoxin A

5,506

Literatures (Medical) associated with Onabotulinumtoxin A

31 Dec 2026·Hematology

Treatment patterns of bone-targeted agents for the prevention of skeletal-related events in multiple myeloma in Bulgaria: a cross-sectional chart review study

Article

Author: Katrandzhieva, Zornitsa ; Mihaylov, Georgi ; Ianakieva, Valentina ; Goranova-Marinova, Veselina ; Karaasenov, Kristiyan

BACKGROUND:

Bone disease (MBD) is common in patients with multiple myeloma (MM) and ~80% are already affected at diagnosis. MBD increases the risk of skeletal-related events (SREs) and the use of bone-targeted agents (BTAs) is recommended for their prevention and treatment.

METHODS:

This study retrospectively analyzed electronic health records of adults with MBD treated in real-world practice in any of eight hematology clinics in Bulgaria. The study assessed patients' demographics and clinical characteristics, BTA treatment patterns and pain management, and estimated the incidence of SREs and osteonecrosis of the jaw (ONJ).

RESULTS:

The study included 732 patients (denosumab: 177; zoledronic acid: 440; zoledronic acid and denosumab sequentially: 115). In 83%, 84%, and 84% of patients, respectively, the first recorded therapy contained a BTA either alone or in combination with an anti-myeloma therapy. The median (Q1, Q3) duration of BTA administration was longer in patients receiving both BTAs sequentially (zoledronic acid: 84 [24, 157] days; denosumab: 60 [0, 197] days). BTAs were prescribed mostly in preventive intent: only 22%, 16%, and 30%, respectively, had experienced previous SREs. While receiving BTAs, new SREs occurred in 9%, 7%, and 9%, respectively. Seven cases of ONJ were identified but only one occurred during BTA use (in the zoledronic acid cohort).

CONCLUSIONS:

Patients with MM are at very high risk of SREs. When receiving BTAs with a preventive intent, only a minority (<10%) experienced an SRE. These data suggest that preventive BTA use, effectively reduces the risk of SREs in real-life clinical practice.

01 Jun 2026·VETERINARY JOURNAL

The effect of intradermal botulinum toxin type A injection on healing of porcine full-thickness wounds

Article

Author: Durongpongtorn, Sumit ; Darapong, Panadda ; Kaewamatawong, Theerayuth ; Brikshavana, Pasakorn

Botulinum toxin type A (BTX-A) has been proposed to improve wound healing quality beyond its neuromuscular effects; however, histopathologic evidence from translational skin models remains limited. This study evaluated the effects of intradermal BTX-A on cutaneous wound healing using a porcine full-thickness wound model. Ten standardized circular wounds were created and treated with intradermal BTX-A or saline as a control. Wound area and histopathological parameters-including inflammatory cell infiltration, differential inflammatory cell counts, blood vessel density, fibroblast proliferation, collagen density, and collagen fiber organization-were assessed at postoperative day 3, 7, 14, 21, and 28. Wound area decreased progressively in both groups, with no significant differences in wound closure kinetics. In contrast, BTX-A-treated wounds exhibited significantly reduced inflammatory cell infiltration during the early postoperative period, with decreased neutrophil, lymphocyte, and macrophage counts at selected time points (p < 0.05). Blood vessel density and fibroblast counts were significantly increased in BTX-A-treated wounds during the early proliferative phase (p < 0.05). Collagen density was consistently higher in BTX-A-treated wounds at all time points, and collagen fiber organization was significantly improved during the remodeling phase. These findings indicate that intradermal BTX-A improves wound healing quality by modulating inflammation, angiogenesis, fibroplasia, and collagen maturation without accelerating wound closure.

01 May 2026·JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY

Evaluation of the ultrasonography-guidance for botulinum toxin type a injection into lateral pterygoid muscle in patients with TMJ anterior disc displacement with reduction

Article

Author: Nowair, Ibrahim Mohamed ; Abu-Shahba, Ahmed Gamal ; Abdelghany Elbrol, Mohamed Shebl ; Othman, Rosie Abdulqahar

Anterior disc displacement with reduction (ADDwR) is a common temporomandibular joint disorder associated with pain, joint sounds, and limited jaw movement. Conservative treatments are considered first-line but often yield unsatisfactory results. Botulinum toxin type A (BTX-A) injection into the lateral pterygoid muscle (LPM) offers a minimally invasive alternative, and ultrasonography enhances safety and accuracy through real-time, radiation-free guidance. This single-arm clinical trial included ten patients (20 TMJs), aged 19-38 years, diagnosed with ADDwR. Each patient received 25 units of BTX-A into the LPM under ultrasound guidance. Clinical outcomes, including pain (NPRS), clicking sound, maximum interincisal opening (MIO), and lateral excursion of the mandible, were assessed at 2, 6, 12, and 24 weeks. MRI was performed at baseline and 12 weeks to evaluate disc position, while Fonseca's questionnaire was applied preoperatively and at 24 weeks. Significant improvements were observed in pain, clicking, MIO, and lateral excursion, with MRI confirming improved disc position at 12 weeks and Fonseca scores demonstrating marked improvement at 24 weeks. The findings suggest that ultrasound-guided BTX-A injection into the LPM is a safe and effective treatment for ADDwR, enhancing joint function and symptom relief, although larger randomized studies are recommended.

398

News (Medical) associated with Onabotulinumtoxin A

27 Apr 2026

·endpoints.news

Veradermics wins at growing hair with oral Rogaine in late-stage trial

Veradermics has succeeded in its first major test as a newly-minted public company. The biotech’s form of oral Rogaine cleared the bar in a Phase 2/3 trial in men with mild-to-moderate pattern hair loss, producing statistically significant improvement in hair growth starting as early as month two. Both once- and twice-daily versions of the drug, called VDPHL01, led to “rapid and robust hair growth,” Veradermics said on Monday. At month six, once-daily dosing led to an increase of target area hair count of 30.3 hairs/cm², while the twice-daily patients experienced a 33.0 hairs/cm² increase. Placebo participants saw a 7.3 hairs/cm² improvement. The growth is measured by photographing the same square centimeter, as located by a red spot tattooed on the head, over the course of the study. The photos are assessed via a digital analysis algorithm from a vendor with more than three decades of experience in the field, CEO Reid Waldman told Endpoints News. The study’s patient-reported outcome (PRO) co-primary endpoint also came in at a high mark. About 79% and 86% of patients on the once- and twice-daily regimens, respectively, reported PRO improvements. About 36% of placebo participants could say the same. The PRO involved patients looking at themselves at baseline and then again at their six-month follow-up visit. They assessed their hair on a seven-point scale that goes from “much worse” to “much improved.” The trial included more than 500 participants. Waldman, a trained dermatologist, said the data beat internal expectations. Going into the readout, Veradermics’ success benchmark was “a profile that essentially would look like an oral Rogaine foam with good safety but the convenience of oral administration,” Waldman said. “And that is a profile that we have just smashed with this data,” he added. The company said Monday the drug’s safety and tolerability were “similar to placebo.” About 5% of patients experienced lower extremity edema, but only 1% discontinued the study for that reason, Waldman said. About 5% of patients experienced hypertrichosis, or excessive hair growth, but there were no discontinuations for that adverse event, he added. VDPHL01 is a non-hormonal medicine and is an oral version of minoxidil, long known as Rogaine. Oral versions have been taken off-label for hair loss before but heart issues have caused hiccups for broader use. Veradermics has been working for almost seven years on an extended-release version with a gel matrix that delivers the drug more slowly and gets rid of those cardiac concerns. There’s another Phase 3 trial in men to read out in the second half of this year. Veradermics will likely then submit the drug for FDA approval. Another Phase 3 in women could be submitted at the same time or at a later date, Waldman said. The company plans to apply the burgeoning direct-to-consumer pharma model to the hair growth industry. With the popularity of GLP-1 medicines for obesity and medical cosmetic products like Botox, the company has precedent to work off of in terms of mapping out its commercial future. The New Haven-based biotech believes pattern hair loss is the “largest aesthetics market worldwide,” with 80 million people in the US alone having pattern hair loss. Waldman said Veradermics is “laser-focused this year on building a credible and independent commercial organization.” The company already has a veteran chief commercial officer who is preparing for market launch. It said last month that it has enough money to get into 2029, including fuel for a potential commercial entry. The company bagged more than $250 million in its NYSE entry in early February. The market was happy. Its shares $MANE popped 122% in that first trading session.

Phase 3Clinical Result

25 Apr 2026

·www.prnewswire.com

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for trenibotulinumtoxinE (TrenibotE) related to manufacturing processes; no additional clinical studies are requested As the leader in neurotoxin development and manufacturing, AbbVie is well positioned to address all comments in a timely manner April 23, 2026 -- AbbVie (NYSE: ABBV) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE), a first-in-class botulinum neurotoxin serotype E with a rapid onset of effect and short duration. In its letter, the FDA requested additional information about manufacturing processes. The CRL does not identify any safety or efficacy concerns for TrenibotE, and does not request additional clinical studies. AbbVie is confident that it can address the FDA's comments promptly and expects to submit a thorough response in the coming months. "We strongly believe trenibotulinumtoxinE is an important innovation in botulinum toxin science, with the potential to expand options for patients interested in facial aesthetics," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "Though disappointed, we remain confident in the strength and integrity of our application, and we are well positioned to respond to the agency's feedback promptly to support completion of the review." Regulatory reviews for TrenibotE in other countries are ongoing and progressing as expected. TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and short duration of effect of 2-3 weeks. The safety and efficacy of TrenibotE are supported by data from over 2,100 patients treated with TrenibotE in the clinical program, which included two pivotal Phase 3 clinical studies evaluating TrenibotE for the treatment of moderate to severe glabellar lines and a Phase 3 open-label safety study. At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

24 Apr 2026

·www.fiercepharma.com

FDA snubs AbbVie's prospective Botox heir amid series of manufacturing-related CRLs

Both companies plan to resubmit their products for approval. The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective therapies from AbbVie and Grace Therapeutics. For AbbVie, the Chicago drugmaker had been looking to bolster its industry-leading aesthetics portfolio with a fast-acting follow-on to its blockbuster Botox franchise in trenibotulinumtoxinE (TrenibotE). TrenibotE is a first-in-class botulinum neurotoxin serotype E that could comprise a new option for those looking to treat moderate to severe glabellar lines with a short duration of aesthetic effect. AbbVie's experimental injection is meant to last two to three weeks versus the standard months-long duration of effect with Botox.However, the FDA has now requested more information on AbbVie’s manufacturing processes for the product, the company said Thursday. The CRL doesn’t flag any safety or efficacy concerns or request additional clinical data, with AbbVie maintaining confidence that it can address the agency’s comments “promptly” with a “thorough response” in the coming months. "We strongly believe trenibotulinumtoxinE is an important innovation in botulinum toxin science, with the potential to expand options for patients interested in facial aesthetics," AbbVie’s chief scientific officer and EVP of R&D, Roopal Thakkar, M.D., commented in a company release. "Though disappointed, we remain confident in the strength and integrity of our application, and we are well-positioned to respond to the agency's feedback promptly to support completion of the review." The company’s head of aesthetics R&D, Darin Messina, Ph.D., previously said that the product “has the potential to transform the aesthetic toxin treatment landscape for new patients,” as it allows prospective users to experience a quick “trial” use of Botox before going for the longer-lasting version. The injection takes effect as soon as eight hours after administration, whereas standard Botox takes a few days to set in. A new addition to AbbVie’s Botox portfolio could help boost declining sales, with the company's cosmetic Botox revenues slipping 4.3% in 2025. The company made $4.86 billion in global aesthetics sales last year, a 6.1% decline from 2024, of which $2.6 billion came from Botox in its cosmetic uses. The drug franchise is also indicated for several therapeutic uses, including chronic migraines and overactive bladder, from which it collected $3.7 billion in separately reported sales last year. Botox has been a go-to aesthetic treatment since its 2002 approval for its first cosmetic use, with AbbVie taking ownership through its 2020 acquisition of Allergan. The drug is a plasma-derived product that AbbVie has recently been looking to defend against Inflation Reduction Act (IRA) price reductions, citing the IRA’s purported exclusion of plasma drugs from pricing controls. Rejection for Grace Therapeutics AbbVie wasn’t the only drugmaker to receive bad news from the FDA this week. In a separate action, the agency rejected Grace Therapeutics’ injectable form of nimodipine in aneurysmal subarachnoid hemorrhage (aSAH). The asset is coded as GTx-104. The FDA's qualms came down to the non-clinical section of Grace’s drug application, the company said. Specifically, the FDA cited issues with leachables data for product packaging, as well as non-clinical toxicology risk assessments and “product manufacturing deficiencies” at Grace’s contract manufacturing organization. Still, the company is “confident in the robust data package” that supports its submission and believes that the issues can be addressed in a resubmission, CEO Prashant Kohli said. Grace will now request a Type A meeting with the agency to discuss next steps for a potential path forward. Nimodipine has been used to treat patients with subarachnoid hemorrhage since 1988, when it was first introduced as a capsule. In 2013, an oral solution of the drug hit the market to help reduce hospital administration errors that had caused patient deaths in the past. Grace’s version uses a “unique nanoparticle technology” that supports a water-based formulation of an insoluble drug product for a standard IV infusion, potentially eliminating the need for nasogastric tube administration in patients who are unconscious or otherwise can’t swallow, according to the company. In a study of patients hospitalized with aSAH, those who received Grace’s GTx-104 charted a 19% reduction in at least one incidence of clinically significant hypotension compared to those who were given oral nimodipine. Grace’s therapy was also supported by additional observed benefits, including fewer ICU readmissions and ventilator days, plus a greater percentage of patients who had favorable functional outcomes at 90 days after receiving the drug. There were eight deaths within the GTx-104 arm of the trial, but all deaths across the study were attributed to the severity of the patient’s underlying disease, Grace said. The condition is caused by a ruptured brain aneurysm, which causes bleeding in the subarachnoid space between the brain and the skull and can lead to aSAH, an uncommon type of stroke with a high mortality rate.

AcquisitionDrug ApprovalClinical Result

100 Deals associated with Onabotulinumtoxin A

External Link

KEGG	Wiki	ATC	Drug Bank
D08957	Onabotulinumtoxin A	M03AX01	DB00083

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Masticatory Muscles, Hypertrophy Of	China	Allergan, Inc.	03 Jun 2024
Dystonia	United States	AbbVie, Inc.	22 Aug 2022
Neurogenic detrusor overactivity	United States	AbbVie, Inc.	22 Aug 2022
Dysphonia	Japan	GSK Plc	25 May 2018
Bladder dysfunction	United States	AbbVie, Inc.	04 Apr 2017
Lateral Canthal Lines	United States	AbbVie, Inc.	11 Sep 2013
Limb spasticity	United States	AbbVie, Inc.	09 Mar 2010
Equinus Deformity	Japan	Allergan, Inc.	21 Jan 2009
Hyperhidrosis	Japan	Allergan, Inc.	21 Jan 2009
Skin Diseases	Japan	Allergan, Inc.	21 Jan 2009
Urinary Bladder, Neurogenic	Japan	Allergan, Inc.	21 Jan 2009
Cervical Dystonia, Primary	Japan	GSK Plc	03 Oct 2005
Muscle Spasticity	-	Genesis Healthcare, Inc.	03 Oct 2005
Muscle Cramp	China	Allergan Pharmaceuticals Ireland ULC	22 Apr 2003
Torticollis	Japan	GSK Plc	20 Jun 2000
Talipes	Japan	GSK Plc	23 Feb 2000
Hemifacial Spasm	Japan	GSK Plc	18 Jan 2000
Blepharospasm	Australia	AbbVie Pty Ltd.	09 Jul 1999
cervical dystonia	Australia	AbbVie Pty Ltd.	09 Jul 1999
Crow's feet	Australia	AbbVie Pty Ltd.	09 Jul 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Migraine With Aura	Phase 3	United States	AbbVie, Inc.	05 Nov 2021
Migraine With Aura	Phase 3	Canada	AbbVie, Inc.	05 Nov 2021
Migraine With Aura	Phase 3	Czechia	AbbVie, Inc.	05 Nov 2021
Migraine With Aura	Phase 3	Germany	AbbVie, Inc.	05 Nov 2021
Migraine With Aura	Phase 3	Israel	AbbVie, Inc.	05 Nov 2021
Migraine With Aura	Phase 3	Poland	AbbVie, Inc.	05 Nov 2021
Migraine With Aura	Phase 3	Spain	AbbVie, Inc.	05 Nov 2021
Migraine With Aura	Phase 3	Sweden	AbbVie, Inc.	05 Nov 2021
Migraine With Aura	Phase 3	United Kingdom	AbbVie, Inc.	05 Nov 2021
Migraine Without Aura	Phase 3	United States	AbbVie, Inc.	05 Nov 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAD2026	Phase 3	Glabellar frown lines	992	TrenibotulinumtoxinE 700 U	mpxpfbjfmk(rmptnzhhlx) = wfhriaxskf rfwrydthqu (ztwodjtjze ) View more	Positive	27 Mar 2026
NCT05158166 (CTgov)	Phase 1/2	Spastic Dysphonia	22	DaxibotulinumtoxinA	kgnenlxiee(luqcjxbflt) = bcbybwykkf oaaimgavhv (crgsnmdlbu, 8.18) View more	-	27 Mar 2026
NCT05100199 (CTgov)	Phase 2	Glabellar frown lines	328	Placebo (Placebo)	ngmbynlakx = rzyhughond whghemlkbq (svmphaszmh, atrsoqrwuc - nssvykuzio) View more	-	09 Sep 2025
NCT05100199 (CTgov)	Phase 2	Glabellar frown lines	328	OnabotulinumtoxinA X (OnabotulinumtoxinA X Dose A)	ngmbynlakx = ewfbeonpvv whghemlkbq (svmphaszmh, mghecqooag - vandzomayj) View more	-	09 Sep 2025
NCT06218251 (UFL BOND 974, CTgov)	Phase 4	Facial wrinkles	100	BOTOX	bpdxcwweuc = nsgadkldmg rhkzpdmdiq (bgahotepio, ioxuapsoqx - jbqwphsuok) View more	-	06 Aug 2025
NCT04609020 (CTgov)	Phase 4	Skin Diseases \| Wrinkling of skin	64	Lidocaine+BOTOX	yxottzzmum(onouzeyxot) = lifamsriqr ilkhzcgiru (rxqnzvmvff, 23.61) View more	-	17 Jun 2025
NCT04965311 (CTgov)	Phase 2	Pancreatic Fistula \| Pancreatic Cancer	4	Botulinum Toxin Type A	xsgivqnveb = dprqepcpjm bughtsfjbw (timsnkmpzq, sygcflxerb - rppnaclbhs) View more	-	13 May 2025
NCT01686581 (REPOSE, Pubmed \| BMC Neurol)	Phase 3	Migraine Disorders	641	155 U onabotulinumtoxinA	rqahgvsdax(qtlpakfvkl) = Adverse drug reactions (ADR) were reported in 51/218 in the 155 U group and 10/77 participants in the 156 U - 195 U group; serious adverse drug reactions were 3/218 and 1/77, respectively. The most frequently reported ADR across both dose groups was eyelid ptosis, followed by neck pain, musculoskeletal stiffness nunmgfdrlo (kfezlynhnh ) View more	Positive	06 May 2025
NCT01686581 (REPOSE, Pubmed \| BMC Neurol)	Phase 3	Migraine Disorders	641	156 U - 195 U onabotulinumtoxinA		Positive	06 May 2025
NCT04073303 (CTgov)	Phase 3	-	377	Placebo	btgrgdgfig = awmotsyuxq hzypfnmusf (nfvcjyvowk, jsmxpjzegh - vprsxvyjbz) View more	-	06 May 2025
AAN2025	Not Applicable	Migraine Disorders \| cervical dystonia	279	OnabotulinumtoxinA	clnjkosxpa(rzrtcxclke) = UTI (range 0.7-5.7%) iyrswesuym (mxqrgcxtzs ) View more	Positive	07 Apr 2025
NCT04171531 (MUSA, CTgov)	Phase 3	Urinary Incontinence, Stress \| Urinary Incontinence, Urge	150	Mid-urethral sling	wyfurctmgw(qtdfshmijb) = rmwjqglvus ahbpfqoarc (ucfjormhrr, hxlulcttwi - rxurxtuupc) View more	-	20 Mar 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis